Article

Nanoparticle Drug Delivery More Effective Treating Cancer

Nanoparticles selectively target tumor vessels or cancerous cells.

Nanoparticle targeted drug therapy has been found to be a better option for treating cancer in compared with surgery, radiotherapy, and chemotherapy.

Cancer is the leading cause of death globally, especially in underdeveloped countries, where 82% of the world’s population resides.

It’s expected that by 2030, new cancer diagnoses will increase to 21.7 million and cancer-related deaths will increase to 13 million. This is largely because of population growth and aging.

Although chemotherapy has been found to be the best option in terms of efficacy for treating cancer, especially in those with advanced stage disease, it still destroys healthy tissues and results in systemic toxic reactions.

In order to combat these adverse events, researchers believe targeted drug therapy can work as a possible solution. This form of therapy offers a safer option for delivering toxic medication to the cancerous cells site.

Nanoparticles have an advantage because of their extremely small size. This system shows the potential to be a superior treatment option by selectively targeting tumor vessels or cancerous cells. This is done through the delivery of therapeutic genetic modulators or by incorporating novel or standard anticancer drugs.

This study, published in Current Biotechnology, gives a more clear understanding of the different drug loaded nanocarriers, which provides a unique set of chemical, physical, and photonic properties that better delivery drugs to the tumor tissues.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards